Integrase inhibitor-based antiretroviral treatments decrease oxidative stress caused by HIV infection.

OBJECTIVE

Several chronic illnesses, including HIV infection are associated with oxidative stress. In addition to HIV itself, some antiretrovirals also increase oxidative stress while decreasing viral replication. To investigate the alterations in oxidative stress parameters and thiol-disulphide homeostasis in people living with HIV who were receiving integrase inhibitor-based antiretroviral therapy.

PATIENTS AND METHODS

Thirty treatment-naive adult people living with HIV were prospectively enrolled in the study. Sera were collected from patients twice: at the beginning of antiretroviral therapy (group 1) and 6 months later (group 2). Thirty age-matched healthy volunteers were enrolled in the study as the control group (group 3). Serum levels of total antioxidant status (TAS) and total oxidative status (TOS) were determined using an automated measurement method. Serum malondialdehyde (MDA) and protein carbonyl (PC) levels were measured spectrophotometrically. CD4+ T-cells were counted flow cytometrically. A mathematical equation was used to calculate the oxidative stress index (OSI) and determine disulfide levels (DIS).

RESULTS

TOS, OSI, MDA, and PC levels were significantly increased in treatment-naive people living with HIV than in those receiving ART (p<0.001). Total and native thiol were significantly lower in both HIV-infected groups than in the control group (p<0.001). PC and MDA levels were significantly higher in both HIV-infected groups than in the control group (p<0.001). In correlation analysis, MDA and age were negatively correlated, whereas TAS was positively correlated with CD4+ T-cell count in treatment-naive people living with HIV. Age was positively correlated with TOS (r:0.421, p:0.023) in healthy controls.

CONCLUSIONS

Integrase inhibitor-based antiretroviral treatments decrease the oxidative stress caused by HIV infection and may be a good therapeutic option in people living with HIV.